Dr. Michael Postow on the Toxicities of Melanoma-Treating Targeted Therapy Combinations
March 17th 2016Postow cites the combination of vemurafenib and ipilimumab as one that produced a high rate of liver inflammation and skin rash in patients, which was then deemed not to be given to patients outside of clinical trials.